Asiel Arce-Sillas1, Edgar Sevilla-Reyes2, Diana Denisse Álvarez-Luquín1, Adrian Guevara-Salinas1, Marie-Catherine Boll3, Citzielli Aseret Pérez-Correa1, Alma Viridiana Vivas-Almazan1, Ulises Rodríguez-Ortiz3, Carlos Castellanos Barba4, Marisela Hernandez4, Gladis Fragoso4, Edda Sciutto4, Graciela Cárdenas3, Laura Virginia Adalid-Peralta5,6. 1. Unidad Periférica para el Estudio de la Neuroinflamación en Patologías Neurológicas, Instituto de Investigaciones Biomédicas, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico. 2. Clinica de investigación en enfermedades infecciosas (CIENI), Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico. 3. Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico. 4. Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico. 5. Unidad Periférica para el Estudio de la Neuroinflamación en Patologías Neurológicas, Instituto de Investigaciones Biomédicas, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico, adalid.laura@yahoo.com. 6. Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico, adalid.laura@yahoo.com.
Abstract
OBJECTIVE: Parkinson's disease (PD) patients are usually treated with L-dopa and/or dopaminergic agonists, which act by binding five types of dopaminergic receptors (DRD1-DRD5). Peripheral immune cells are known to express dopamine receptors on their membrane surface, and therefore they could be directly affected by the treatment. Regulatory cells are the main modulators of inflammation, but it is not clear whether dopaminergic treatment could affect their functions. While only regulatory T cells (Tregs) have been proved to express dopamine receptors, it is not known whether other regulatory cells such as CD8regs, regulatory B cells (Bregs), tolerogenic dendritic cells, and intermediate monocytes also express them. METHODS: The expression of dopamine receptors in Tregs, CD8regs, Bregs, tolerogenic dendritic cells, and intermediate monocytes was herein evaluated. cDNA from 11 PD patients and 9 control subjects was obtained and analyzed. RESULTS: All regulatory cell populations expressed the genes coding for dopamine receptors, and this expression was further corroborated by flow cytometry. These findings may allow us to propose regulatory populations as possible targets for PD treatment. CONCLUSIONS: This study opens new paths to deepen our understanding on the effect of PD treatment on the cells of the regulatory immune response.
OBJECTIVE:Parkinson's disease (PD) patients are usually treated with L-dopa and/or dopaminergic agonists, which act by binding five types of dopaminergic receptors (DRD1-DRD5). Peripheral immune cells are known to express dopamine receptors on their membrane surface, and therefore they could be directly affected by the treatment. Regulatory cells are the main modulators of inflammation, but it is not clear whether dopaminergic treatment could affect their functions. While only regulatory T cells (Tregs) have been proved to express dopamine receptors, it is not known whether other regulatory cells such as CD8regs, regulatory B cells (Bregs), tolerogenic dendritic cells, and intermediate monocytes also express them. METHODS: The expression of dopamine receptors in Tregs, CD8regs, Bregs, tolerogenic dendritic cells, and intermediate monocytes was herein evaluated. cDNA from 11 PDpatients and 9 control subjects was obtained and analyzed. RESULTS: All regulatory cell populations expressed the genes coding for dopamine receptors, and this expression was further corroborated by flow cytometry. These findings may allow us to propose regulatory populations as possible targets for PD treatment. CONCLUSIONS: This study opens new paths to deepen our understanding on the effect of PD treatment on the cells of the regulatory immune response.
Authors: Katharina Robichon; Sven Sondhauss; T William Jordan; Robert A Keyzers; Bronwen Connor; Anne C La Flamme Journal: Sci Rep Date: 2021-02-03 Impact factor: 4.379
Authors: Laura Adalid-Peralta; Alexander Lopez-Roblero; Cynthia Camacho-Vázquez; Marisol Nájera-Ocampo; Adrián Guevara-Salinas; Nataly Ruiz-Monroy; Marlene Melo-Salas; Valeria Morales-Ruiz; Dina López-Recinos; Edgar Ortiz-Hernández; Jocelyne Demengeot; Joel A Vazquez-Perez; Asiel Arce-Sillas; Sandra Gomez-Fuentes; Robert Michael Evans Parkhouse; Gladis Fragoso; Edda Sciutto; Edgar E Sevilla-Reyes Journal: Front Cell Infect Microbiol Date: 2021-04-13 Impact factor: 5.293
Authors: Rui Li; Thomas Francis Tropea; Laura Rosa Baratta; Leah Zuroff; Maria E Diaz-Ortiz; Bo Zhang; Koji Shinoda; Ayman Rezk; Roy N Alcalay; Alice Chen-Plotkin; Amit Bar-Or Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-12-26
Authors: M A Penedo; T Rivera-Baltanás; D Pérez-Rodríguez; J Allen; A Borrajo; D Alonso-Crespo; C Fernández-Pereira; M Nieto-Araujo; S Ramos-García; C Barreiro-Villar; H J Caruncho; J M Olivares; R C Agís-Balboa Journal: Brain Behav Immun Health Date: 2021-01-07